Literature DB >> 8128934

Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases.

O Ifudu1, C C Tan, A L Dulin, B G Delano, E A Friedman.   

Abstract

We studied 201 end-stage renal disease (ESRD) patients sustained on maintenance hemodialysis (MD) (n = 164) and chronic ambulatory peritoneal dialysis (CAPD) (n = 37) to determine (1) the frequency of acute attacks of gouty arthritis (GA) in those ESRD patients who had GA before dialytic therapy, and (2) the incidence of new-onset GA in hyperuricemic long-term (> 12 years) ESRD patients on MD. The 2-month mean of predialysis serum uric acid levels was calculated for each subject and the prevalence of hyperuricemia ascertained. There were 25 patients on MD for more than 12 years, and this group was evaluated and analyzed separately from those patients on dialytic therapy for less than 12 years; the mean of each of their predialysis uric acid values was calculated for each subject for at least 60% of the time they have been on dialysis. Patients who had GA before or after initiation of dialytic therapy were identified, and the frequency of acute attacks of GA determined. The presence of treated hypertension in each subject was noted. Thirteen of 201 patients had clinically active GA before commencing dialytic therapy, and each recalled a minimum of two painful attacks of GA per year before the initiation of ESRD therapy. Mean duration of ESRD for these 13 patients was 25 +/- 3.8 months; painful attacks of GA have not recurred in nine patients (70%), and the frequency of attacks declined by 50% in the remaining four patients (30%), despite persistent hyperuricemia in all 13.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8128934     DOI: 10.1016/s0272-6386(12)80995-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  The 3-Year Incidence of Gout in Elderly Patients with CKD.

Authors:  Vivian S Tan; Amit X Garg; Eric McArthur; Ngan N Lam; Manish M Sood; Kyla L Naylor
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-02       Impact factor: 8.237

3.  Association of incident gout and mortality in dialysis patients.

Authors:  Scott D Cohen; Paul L Kimmel; Robert Neff; Lawrence Agodoa; Kevin C Abbott
Journal:  J Am Soc Nephrol       Date:  2008-05-28       Impact factor: 10.121

Review 4.  Managing Gout in the Patient with Renal Impairment.

Authors:  Eliseo Pascual; Francisca Sivera; Mariano Andrés
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

5.  Chyle and gout causing acute monoarthritis: some unusual findings.

Authors:  Venkata Ranga Rao Kodali; Nigel Andrew Dunn
Journal:  Clin Rheumatol       Date:  2004-07-15       Impact factor: 2.980

6.  Risk of end-stage renal disease associated with gout: a nationwide population study.

Authors:  Kuang-Hui Yu; Chang-Fu Kuo; Shue-Fen Luo; Lai-Chu See; I-Jun Chou; Hsiao-Chun Chang; Meng-Jiun Chiou
Journal:  Arthritis Res Ther       Date:  2012-04-18       Impact factor: 5.156

7.  Management of Gout and Hyperuricemia in CKD.

Authors:  Ana Beatriz Vargas-Santos; Tuhina Neogi
Journal:  Am J Kidney Dis       Date:  2017-04-26       Impact factor: 8.860

8.  [Renal diseases in rheumatology].

Authors:  M Janneck; J Velden; C Iking-Konert
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

9.  New and improved strategies for the treatment of gout.

Authors:  Natalie Dubchak; Gerald F Falasca
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-11-24

10.  Febuxostat for hyperuricemia in patients with advanced chronic kidney disease.

Authors:  Tetsu Akimoto; Yoshiyuki Morishita; Chiharu Ito; Osamu Iimura; Sadao Tsunematsu; Yuko Watanabe; Eiji Kusano; Daisuke Nagata
Journal:  Drug Target Insights       Date:  2014-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.